Last reviewed · How we verify
Talazoparib plus Irinotecan — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Talazoparib plus Irinotecan (Talazoparib plus Irinotecan) — QuantumLeap Healthcare Collaborative.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Talazoparib plus Irinotecan TARGET | Talazoparib plus Irinotecan | QuantumLeap Healthcare Collaborative | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Talazoparib plus Irinotecan CI watch — RSS
- Talazoparib plus Irinotecan CI watch — Atom
- Talazoparib plus Irinotecan CI watch — JSON
- Talazoparib plus Irinotecan alone — RSS
Cite this brief
Drug Landscape (2026). Talazoparib plus Irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/talazoparib-plus-irinotecan. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab